Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
about
Profile of gantenerumab and its potential in the treatment of Alzheimer's diseaseStressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions.Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Novel information on the non-neuronal cholinergic system in orthopedics provides new possible treatment strategies for inflammatory and degenerative diseasesAcid sphingomyelinase deficiency increases susceptibility to fatal alphavirus encephalomyelitis.Fetal microglial phenotype in vitro carries memory of prior in vivo exposure to inflammationCholinergic control of inflammationPeripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseasesIdentification and treatment of symptoms associated with inflammation in medically ill patients.Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease.Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementiaPlasma acetylcholinesterase activity correlates with intracerebral β-amyloid loadNew treatments for myasthenia: a focus on antisense oligonucleotides.Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links.LPS and neuroinflammation: a matter of timing.Peripheral injection of SB203580 inhibits the inflammatory-dependent synthesis of proinflammatory cytokines in the hypothalamus.Evaluation of cholinesterase activities during in vivo intoxication using an electrochemical sensor strip - correlation with intoxication symptoms.Investigation into the role of the cholinergic system in radiation-induced damage in the rat liver and ileum.Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer's disease modelBlood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.Nicotinic acetylcholine receptors mediate donepezil-induced oligodendrocyte differentiation.Peripheral Inhibitor of AChE, Neostigmine, Prevents the Inflammatory Dependent Suppression of GnRH/LH Secretion during the Follicular Phase of the Estrous Cycle.Chronic hyperhomocysteinemia increases inflammatory markers in hippocampus and serum of rats.Redefining the role of peripheral LPS as a neuroinflammatory agent and evaluating the role of hydrogen sulphide through metformin intervention.Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet.Donepezil promotes differentiation of neural stem cells into mature oligodendrocytes at the expense of astrogenesis.Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study.Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury.A Logic Model of Neuronal-Glial Interaction Suggests Altered Homeostatic Regulation in the Perpetuation of NeuroinflammationNeostigmine Attenuates Proinflammatory Cytokine Expression in Preoptic Area but Not Choroid Plexus during Lipopolysaccharide-Induced Systemic InflammationEffect of Essential Oils from Ginger () and Turmeric () Rhizomes on Some Inflammatory Biomarkers in Cadmium Induced Neurotoxicity in Rats
P2860
Q27027675-739F34F8-3DFC-404B-90A3-B8B73FBC6EE5Q30469329-30AE375E-9B9E-4DC8-9EA5-FFA1F9974BC7Q33715239-25EF4DDC-B71D-4899-B253-264DDBB0F992Q35128863-F1AC00A3-01E5-4D4B-AA32-D5D7975D62CEQ35139602-D745AC1C-8842-44A8-A3F7-B2201435672AQ35914135-A5BC58AD-339D-4C95-9552-51DA11E71F39Q35966390-2FCD02EC-0B82-41AE-A4DB-E2F08456A47BQ36023238-A46B9503-0F16-42D4-B28F-A573E7FC3F7AQ36447488-70489229-1131-4EA8-8916-D2538A7A40BBQ36571755-594E76A3-8895-40BE-B2D1-E82726411755Q36846711-DE4CC562-191F-4927-8173-A33F4CBE5219Q37063986-5997B829-D6EE-414E-8EDD-8B7A409FEC9BQ37158584-1F6AD712-7F69-4E40-AEC6-DFA6FB4698AEQ38076108-AD072FD2-2147-45F7-BB76-0D637EE7C66FQ38298811-BC248DA4-D00F-4505-9246-6810420DE5F9Q38958986-92DB7010-1EE0-4F4C-875F-CBF0D84E99F7Q40962111-94331D1B-5DC3-4AF0-8049-2384FF5D43A7Q41945181-291643FD-791A-4864-A35D-A5188907B134Q42100775-FC8B0FAB-19E9-48D8-97FB-E27169FD3BD5Q42276602-2BA2FC12-C8D3-411C-8044-30779E36CFD3Q44709746-E374DA8A-35CD-4B46-96A1-17449C36D4D8Q47910897-3CE21DEE-1B7C-4BE7-A790-8B3D8151EB5CQ48089664-C5E2C312-7587-420C-9744-BFA5FA3D6988Q48578754-2D280812-51A7-45D4-9939-F0BA1B381D7CQ48589396-AC3BE585-A124-4BC5-9C2B-BD2CEA2F8940Q50472663-D961873D-AE55-4119-9651-598CEFF69316Q51466628-752811E1-6A39-4F1E-8FAE-E1933337B127Q55402006-469BCAA0-D731-40E3-B154-EA1AC8CEE45BQ55468554-98D63A5D-AF5E-4F85-9017-89021CAF549FQ58122012-0C4D23B8-C792-425C-BB37-24EC4BA78F6DQ58578849-DB86DF5B-3F7D-480F-9E79-0168C532829FQ58580691-65E3D9A0-1822-47C2-A759-6D968951AC04
P2860
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
@en
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
@nl
type
label
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
@en
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
@nl
prefLabel
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
@en
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
@nl
P2093
P356
P1433
P1476
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production
@en
P2093
Adi Gilboa
Ofra Ben-Menachem
Tamir Ben-Hur
Yehuda Pollak
P304
P356
10.1002/ANA.20454
P577
2005-05-01T00:00:00Z